MX2013001612A - Moduladores de trpv3 novedosos. - Google Patents

Moduladores de trpv3 novedosos.

Info

Publication number
MX2013001612A
MX2013001612A MX2013001612A MX2013001612A MX2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A
Authority
MX
Mexico
Prior art keywords
novel
trpv3
trpv3 modulators
modulators
compositions
Prior art date
Application number
MX2013001612A
Other languages
English (en)
Inventor
Michael E Kort
Arthur Gomtsyan
Erol K Bayburt
Jerome F Daanen
Philip R Kym
Bruce Clapham
Eric A Voight
Phil B Cox
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013001612A publication Critical patent/MX2013001612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente solicitud se describen moduladores de TRPV3 de la fórmula (I), en la cual G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, y p son como se definen en la descripción. También se presentan composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones.
MX2013001612A 2010-08-10 2010-08-10 Moduladores de trpv3 novedosos. MX2013001612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/001213 WO2012019315A1 (en) 2010-08-10 2010-08-10 Novel trpv3 modulators

Publications (1)

Publication Number Publication Date
MX2013001612A true MX2013001612A (es) 2013-07-05

Family

ID=45567252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001612A MX2013001612A (es) 2010-08-10 2010-08-10 Moduladores de trpv3 novedosos.

Country Status (13)

Country Link
US (1) US9156788B2 (es)
EP (1) EP2603490A4 (es)
JP (1) JP2013538800A (es)
KR (1) KR20130097748A (es)
CN (1) CN103140476A (es)
AU (1) AU2010359001A1 (es)
BR (1) BR112013003121A2 (es)
CA (1) CA2807538A1 (es)
CR (1) CR20130106A (es)
MX (1) MX2013001612A (es)
RU (1) RU2013110324A (es)
SG (1) SG187811A1 (es)
WO (1) WO2012019315A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807538A1 (en) 2010-08-10 2012-02-16 Abbvie Inc. Novel trpv3 modulators
WO2012100153A1 (en) * 2011-01-20 2012-07-26 Northeastern University Real-time pavement profile sensing system using air-coupled surface wave
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
CN104254522A (zh) * 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
WO2013062966A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN109942459B (zh) * 2017-12-21 2022-06-24 南京理工大学 一种合成3-二氟甲基-3-丙烯腈类化合物的方法
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138547A (en) * 1978-04-14 1979-10-27 Takeda Chem Ind Ltd Beta-aminoketone derivative and its preparation
JPS60109539A (ja) * 1983-11-15 1985-06-15 Sumitomo Chem Co Ltd ベンジルアルコ−ル誘導体
JPS60230742A (ja) * 1984-04-28 1985-11-16 Shinko Electric Co Ltd ル−プ式デ−タ伝送方式における割込み信号伝送方法
JPS6471830A (en) * 1987-09-11 1989-03-16 Rikagaku Kenkyusho Monofluorocyclobutanes and production thereof
DE3914820A1 (de) * 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4018260A1 (de) * 1990-06-07 1991-12-12 Basf Ag Derivate des (beta)-picolins und diese enthaltende pflanzenschutzmittel
DE4318916A1 (de) * 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1215715A (zh) * 1997-10-28 1999-05-05 兰州大学 立体选择性1,3－二醇合成方法
AU2720199A (en) * 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CA2422055A1 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
US7115414B2 (en) 2001-06-13 2006-10-03 IRM LLC, A Delaware Corp. Vanilloid receptor-related nucleic acids and polypeptides
DE60335869D1 (de) * 2002-04-11 2011-03-10 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
PL376659A1 (pl) * 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TWI401254B (zh) * 2005-05-09 2013-07-11 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
TWI409070B (zh) 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
ATE522519T1 (de) * 2008-03-20 2011-09-15 Hoffmann La Roche Pyrrolidinylderivate und anwendungen davon
NZ595780A (en) * 2008-06-17 2013-07-26 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
WO2010110231A1 (ja) * 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
AR082138A1 (es) * 2010-07-12 2012-11-14 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos
CA2807538A1 (en) 2010-08-10 2012-02-16 Abbvie Inc. Novel trpv3 modulators
WO2013062966A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators

Also Published As

Publication number Publication date
JP2013538800A (ja) 2013-10-17
KR20130097748A (ko) 2013-09-03
CA2807538A1 (en) 2012-02-16
EP2603490A4 (en) 2014-01-01
BR112013003121A2 (pt) 2016-06-28
AU2010359001A1 (en) 2013-03-14
CR20130106A (es) 2013-07-19
US20130150409A1 (en) 2013-06-13
WO2012019315A1 (en) 2012-02-16
EP2603490A1 (en) 2013-06-19
RU2013110324A (ru) 2014-09-20
CN103140476A (zh) 2013-06-05
US9156788B2 (en) 2015-10-13
SG187811A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PH12018501711A1 (en) Compounds for treating spinal muscular atrophy
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2013011054A (es) Antagonistas de trpvi.
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
IN2012DN03883A (es)
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
MX2013001612A (es) Moduladores de trpv3 novedosos.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
IN2015DN00960A (es)
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX352962B (es) Compuestos para tratar atrofia muscular espinal.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
MX2014002770A (es) Nuevos derivados dihidroquinolina-2-ona.
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MY169267A (en) New aryl-quinoline derivatives
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
TN2009000536A1 (en) Novel herbicides
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MX2011010046A (es) Derivados de diaminopteridina.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal